<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17578" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Angiomyolipoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Skelton</surname>
            <given-names>William P.</given-names>
          </name>
          <aff>University of Virginia Comprehensive Cancer Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>William Skelton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17578.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Renal angiomyolipomas are the most prevalent benign renal tumors characterized by a composition of blood vessels, smooth muscles, and adipose tissues in varying amounts.&#x000a0;Although most of these tumors are&#x000a0;often discovered incidentally during imaging, symptomatic presentations such as flank pain, gross hematuria, or severe retroperitoneal hemorrhage may also exist. These tumors are distinct from hamartomas and malignant Grawitz tumors. Imaging plays a crucial role in diagnosing and managing&#x000a0;renal angiomyolipomas.&#x000a0;</p>
        <p>Classic angiomyolipomas exhibit abundant adipose tissue on radiological scans. Management strategies vary based on clinical presentation, tumor characteristics, and associated conditions, offering options from active surveillance to treatment with mammalian target of rapamycin (mTOR) inhibitors or surgical interventions. Although most cases occur sporadically, some are linked to hereditary conditions such as tuberous sclerosis or pulmonary lymphangioleiomyomatosis.&#x000a0;This activity comprehensively reviews the evaluation, treatment, complications, and prognosis of renal angiomyolipomas while emphasizing the crucial role of the interprofessional healthcare team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the characteristic imaging findings of renal angiomyolipoma on ultrasound, computed tomography scan, and magnetic resonance imaging.</p></list-item><list-item><p>Screen patients with tuberous sclerosis complex or pulmonary lymphangioleiomyomatosis for renal angiomyolipoma.</p></list-item><list-item><p>Implement evidence-based management strategies for renal angiomyolipoma, including active surveillance, embolization, and surgical resection, based on tumor size, symptoms, and patient preferences.</p></list-item><list-item><p>Collaborate with multidisciplinary healthcare teams to optimize complex cases of renal angiomyolipoma and monitor for recurrence and complications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17578&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17578">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17578.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Renal angiomyolipomas are the most prevalent benign renal tumor.<xref ref-type="bibr" rid="article-17578.r1">[1]</xref>&#x000a0;First&#x000a0;described by Grawitz in 1900, renal angiomyolipomas are generally highly vascular tumors primarily composed of blood vessels, smooth muscles, and mature adipose tissues and are distinguished by perivascular epithelioid differentiation.<xref ref-type="bibr" rid="article-17578.r2">[2]</xref>&#x000a0;Although&#x000a0;most of these tumors are&#x000a0;often discovered incidentally during radiological imaging, symptomatic presentations such as flank pain, gross hematuria, or severe retroperitoneal hemorrhage may also exist.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref>&#x000a0;</p>
        <p>Angiomyolipomas are occasionally misidentified as hamartomas. However, while both are benign, the distinction lies in their nature&#x02014;an angiomyolipoma is a genuine tumor, whereas a hamartoma constitutes a disorganized aggregation of normal local tissue and cells, often resulting from trauma, infection, infarction, obstruction, or hemorrhage. Notably, although Grawitz first described renal angiomyolipomas, they are distinct from Grawitz tumors, which are malignant renal cell carcinomas and hypernephromas.</p>
        <p>Imaging plays a central role in the diagnosis and management of renal angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r4">[4]</xref>&#x000a0;These tumors comprise variable amounts of 3 tissue elements&#x02014;vascular, muscular, and adipose. These variations manifest in distinct pathological, radiological, and clinical features.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p>
        <p>The key diagnostic criterion of classic angiomyolipoma is identifying a significant amount of adipose tissue on radiological imaging.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;Although considered benign, the tumors may extend into the surrounding perirenal fat or renal sinus, as well as nearby organs and lymphatics.<xref ref-type="bibr" rid="article-17578.r7">[7]</xref>&#x000a0;Rare reports also indicate isolated instances of tumor thrombi extending through the renal vein into the vena cava.<xref ref-type="bibr" rid="article-17578.r8">[8]</xref><xref ref-type="bibr" rid="article-17578.r9">[9]</xref></p>
        <p>Management of angiomyolipomas is determined by factors such as clinical symptoms, tumor size, number, growth pattern, and potential for malignancy.<xref ref-type="bibr" rid="article-17578.r2">[2]</xref><xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;For instance, epithelioid angiomyolipoma of the kidney, a rare subtype of angiomyolipoma, is regarded as potentially malignant.<xref ref-type="bibr" rid="article-17578.r10">[10]</xref></p>
      </sec>
      <sec id="article-17578.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Renal angiomyolipomas primarily occur as isolated "sporadic" cases (80%) but may also be associated with certain "hereditary" conditions (20%), such as tuberous sclerosis and pulmonary lymphangioleiomyomatosis.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref><xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Although the exact cause of sporadic cases remains unknown, some researchers postulate that it results from a spontaneous genetic mutation.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;</p>
        <p>Hereditary angiomyolipomas, associated with&#x000a0;tuberous sclerosis complex or pulmonary lymphangioleiomyomatosis, result from a genetic mutation in the <italic toggle="yes">TSC1</italic>&#x000a0;or&#x000a0;<italic toggle="yes">TSC2&#x000a0;</italic>genes.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r11">[11]</xref>&#x000a0;These mutations affect the mammalian target of rapamycin (mTOR), which explains the response of these angiomyolipomas to mTOR inhibitors such as sirolimus and everolimus.<xref ref-type="bibr" rid="article-17578.r12">[12]</xref></p>
        <p>In contrast to the more common sporadic type, hereditary angiomyolipomas, which are associated with tuberous sclerosis or lymphangioleiomyomatosis, are likely to be larger, begin at an earlier age, display&#x000a0;multicentric and bilateral growth, have a faster growth rate, be prone to hemorrhage, contribute to chronic renal failure, and be more prone to malignant transformation.<xref ref-type="bibr" rid="article-17578.r13">[13]</xref><xref ref-type="bibr" rid="article-17578.r14">[14]</xref></p>
        <p>
<bold>Causes of Renal Angiomyolipomas&#x000a0;</bold>
</p>
        <p><bold>Tuberous sclerosis:</bold>&#x000a0;This is a rare, familial, autosomal dominant genetic disorder characterized by the development of benign tumors in various body parts, typically affecting the brain, eyes, heart, lungs, and kidneys. Tuberous sclerosis is also associated with adenoma sebaceum, epilepsy, and mental deficiencies. Although the overall incidence of tuberous sclerosis is estimated at about 1&#x000a0;per 10,000 population, it is believed to be significantly underdiagnosed. Tuberous sclerosis does not exhibit racial or sexual predilection. Over 50% of individuals with tuberous sclerosis will eventually develop renal angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref></p>
        <p>Tuberous sclerosis is usually diagnosed by the discovery of benign tumors in the brain, kidneys, heart, liver, and lungs. Initial symptoms often manifest as neurological, including seizures, mental deficiencies, autism, behavioral challenges (such as obsessive-compulsive disorder or overly aggressive tendencies), learning disabilities, and developmental delays.&#x000a0;In addition, this condition is also associated with various skin manifestations.&#x000a0;A definitive diagnosis can usually be made by genetic testing for&#x000a0;the&#x000a0;<italic toggle="yes">TSC1</italic>&#x000a0;or&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;genes.<xref ref-type="bibr" rid="article-17578.r15">[15]</xref>&#x000a0;Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/30666">Tuberous Sclerosis</ext-link>," for further information.</p>
        <p>Patients diagnosed with tuberous sclerosis typically present with larger renal angiomyolipomas (32% exceeding 3 cm), a higher likelihood of bilateral and multifocal lesions, and double the rate of tumors that increase in size over time compared to individuals without tuberous sclerosis who have renal angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r17">[17]</xref><xref ref-type="bibr" rid="article-17578.r18">[18]</xref>&#x000a0;In addition, the epithelioid variant of angiomyolipoma in these patients is more prone to malignant transformation.<xref ref-type="bibr" rid="article-17578.r19">[19]</xref>&#x000a0;Among women with tuberous sclerosis, 40% will exhibit some degree of pulmonary lymphangioleiomyomatosis, as described below.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r20">[20]</xref><xref ref-type="bibr" rid="article-17578.r21">[21]</xref></p>
        <p><bold>Pulmonary lymphangioleiomyomatosis:</bold>&#x000a0;This is an exceedingly rare genetic disorder often associated with angiomyolipomas and occasionally with tuberous sclerosis. The overall incidence is about 5 cases per 1 million women.<xref ref-type="bibr" rid="article-17578.r22">[22]</xref>&#x000a0;This condition typically affects women of childbearing age, causing abnormal smooth muscle cell growth in the lungs.</p>
        <p>Pulmonary lymphangioleiomyomatosis causes cyst formation in the lungs, which can affect pulmonary function, resulting in dyspnea. Approximately 45% to 60% of patients will develop angiomyolipomas in the kidneys, commonly occurring in multiple and bilateral patterns.<xref ref-type="bibr" rid="article-17578.r23">[23]</xref><xref ref-type="bibr" rid="article-17578.r24">[24]</xref><xref ref-type="bibr" rid="article-17578.r25">[25]</xref>&#x000a0;Pulmonary lymphangioleiomyomatosis should be suspected in younger women with interstitial lung disorders. Diagnosis of this condition can be confirmed through biopsy or elevated serum levels of vascular endothelial growth factor-D (VEGF-D).<xref ref-type="bibr" rid="article-17578.r26">[26]</xref></p>
        <p>Patients newly diagnosed with lymphangioleiomyomatosis should undergo renal imaging to screen for angiomyolipomas. However, routine VEGF-D testing for lymphangioleiomyomatosis is not necessary or recommended for most female patients with angiomyolipomas due to its rarity. Nevertheless, it should be considered in younger women with multiple renal angiomyolipomas, particularly if they also present with pulmonary issues. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/24552">Lymphangioleiomyomatosis</ext-link>," for further information.<xref ref-type="bibr" rid="article-17578.r23">[23]</xref></p>
      </sec>
      <sec id="article-17578.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Renal angiomyolipomas are rare kidney tumors that account for only 0.3% to 3% of all renal neoplasms.<xref ref-type="bibr" rid="article-17578.r2">[2]</xref><xref ref-type="bibr" rid="article-17578.r27">[27]</xref>&#x000a0;Their overall prevalence rate ranges from 0.13% to 2.2%, with 80% of cases being sporadic.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref><xref ref-type="bibr" rid="article-17578.r28">[28]</xref><xref ref-type="bibr" rid="article-17578.r29">[29]</xref><xref ref-type="bibr" rid="article-17578.r30">[30]</xref>&#x000a0;The remaining 20% are associated with pulmonary lymphangioleiomyomatosis or tuberous sclerosis complex.<xref ref-type="bibr" rid="article-17578.r28">[28]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref>&#x000a0;</p>
        <p>Renal angiomyolipomas tend to occur in females more than males, possibly due to estrogenic effects.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref> Additionally, the size of the tumors also tends to be larger in females than in males. Pregnant women experience an accelerated growth rate of angiomyolipomas and face a higher risk of hemorrhagic complications.<xref ref-type="bibr" rid="article-17578.r32">[32]</xref><xref ref-type="bibr" rid="article-17578.r33">[33]</xref><xref ref-type="bibr" rid="article-17578.r34">[34]</xref><xref ref-type="bibr" rid="article-17578.r35">[35]</xref>&#x000a0;Furthermore, exogenous estrogen therapy appears to increase the risk of bleeding from angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r36">[36]</xref></p>
        <p>At least 50% to 75% of&#x000a0;individuals diagnosed with tuberous sclerosis will develop renal angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r37">[37]</xref><xref ref-type="bibr" rid="article-17578.r38">[38]</xref><xref ref-type="bibr" rid="article-17578.r39">[39]</xref>&#x000a0;In these cases, the incidence of renal angiomyolipomas increases with age, and the initial presentation of the tumors manifests at a younger age compared to those without tuberous sclerosis (12 versus 24 years).<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166382#link_29697822">[37]</ext-link></p>
      </sec>
      <sec id="article-17578.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact cause of sporadic renal angiomyolipoma remains unknown.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r28">[28]</xref>&#x000a0;All three tissue types appear to originate from pericytes (microcirculatory mural cells), as they express pericyte markers, except for the endothelial cell components that develop independently.<xref ref-type="bibr" rid="article-17578.r40">[40]</xref><xref ref-type="bibr" rid="article-17578.r41">[41]</xref></p>
        <p>A mutation in either the <italic toggle="yes">TSC1</italic> or <italic toggle="yes">TSC2</italic> gene causes tuberous sclerosis and hereditary renal angiomyolipomas<italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-17578.r2">[2]</xref><xref ref-type="bibr" rid="article-17578.r11">[11]</xref>&#x000a0;These 2 genes encode the essential proteins hamartin and tuberin, respectively.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref><xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;The interaction between these 2 proteins forms a tumor suppressor complex,&#x000a0;which&#x000a0;inhibits the mTOR pathway, crucial for cell growth, angiogenesis, and protein synthesis.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r28">[28]</xref>&#x000a0;</p>
        <p>Deficient or defective <italic toggle="yes">TSC1</italic> or <italic toggle="yes">TSC2</italic>&#x000a0;gene activity leads to unchecked activation of the mTOR pathway, which results in the formation of angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r42">[42]</xref>&#x000a0;This&#x000a0;mechanism also elucidates the effectiveness of mTOR inhibitors such as sirolimus and everolimus in reducing tumor size and restraining their growth.&#x000a0;</p>
        <p>Angiomyolipomas are generally considered benign, with a very low likelihood of malignant transformation.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref>&#x000a0;The vast majority (90%) of angiomyolipomas are asymptomatic and tend to remain stable in size. However, only about 9% may gradually increase in size over time.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref>&#x000a0;Larger tumors (&#x0003e;6 cm) are more likely to enlarge,&#x000a0;grow, hemorrhage, and develop symptoms.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref></p>
      </sec>
      <sec id="article-17578.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Renal angiomyolipomas can be histologically classified as either typical (triphasic) or atypical (monophasic or epithelioid).<xref ref-type="bibr" rid="article-17578.r3">[3]</xref><xref ref-type="bibr" rid="article-17578.r44">[44]</xref>&#x000a0;Triphasic angiomyolipomas typically consist of 3 tumor components&#x02014;blood vessels or vascular cells, smooth muscle cells, and mature adipocytes.&#x000a0;Monophasic&#x000a0;angiomyolipomas usually&#x000a0;have a major component, while other elements are typically present only in minimal amounts (see <bold>Image.</bold>&#x000a0;Histology, Renal Angiomyolipoma).<xref ref-type="bibr" rid="article-17578.r3">[3]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref><xref ref-type="bibr" rid="article-17578.r44">[44]</xref></p>
        <p>
<bold>Gross Pathology Descriptions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The mean tumor size measures 6 cm, with a range varying from 0.5 to 25 cm.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A "large" tumor is considered larger than 6 cm, previously defined as 4 cm.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tumors exhibit a circumscribed morphology and lack encapsulation.<xref ref-type="bibr" rid="article-17578.r45">[45]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cystic components within tumors are rare.<xref ref-type="bibr" rid="article-17578.r44">[44]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tumors are usually unifocal and unilateral, although bilateral or multiple occurrences may suggest an underlying tuberous sclerosis.<xref ref-type="bibr" rid="article-17578.r44">[44]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cut surface appearances vary, displaying gray-white (smooth muscle component), red (vascular component), or yellow (adipose component) colors. The characteristic golden-yellow appearance depends on fat content.<xref ref-type="bibr" rid="article-17578.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Invasion into the local perinephric fat, lymphatics, or renal sinus may or may not occur.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Occasionally, tumors may invade the renal vein, forming a tumor thrombus akin to malignant renal tumors, potentially extending intracardiacly and leading to pulmonary embolisms.<xref ref-type="bibr" rid="article-17578.r8">[8]</xref><xref ref-type="bibr" rid="article-17578.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Epitheliod variant typically exhibits minimal fat and may demonstrate metastasis in up to a third of cases.<xref ref-type="bibr" rid="article-17578.r46">[46]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Microscopic Pathology Descriptions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The classic triphasic renal angiomyolipoma exhibits thick-walled, dysmorphic, disorganized, hyalinized blood vessels without elastic lamina.<xref ref-type="bibr" rid="article-17578.r47">[47]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The&#x000a0;tumor comprises mature adipose tissue and myoid spindle cells.<xref ref-type="bibr" rid="article-17578.r45">[45]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The epithelioid variant typically features predominant polygonal cells with densely eosinophilic cytoplasm. Hemorrhage, necrosis, epithelioid cellular proliferation, and mitotic figures are commonly observed.<xref ref-type="bibr" rid="article-17578.r45">[45]</xref><xref ref-type="bibr" rid="article-17578.r48">[48]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal angiomyolipomas with epithelial cysts display cysts lined by cuboidal or hobnail epithelial cells.<xref ref-type="bibr" rid="article-17578.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Biomarkers</bold>
</p>
        <p>Renal angiomyolipomas are comprised of 3 cell types, all originating from pericytes.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r40">[40]</xref>&#x000a0;These cell types include atypical smooth-muscle-like, adipocyte-like, and epithelioid cells.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref> Accordingly, they express pericyte markers.<xref ref-type="bibr" rid="article-17578.r40">[40]</xref><xref ref-type="bibr" rid="article-17578.r45">[45]</xref>&#x000a0;Notably, the expressed pericyte markers&#x000a0;include&#x000a0;angiotensin II type 1 receptor, platelet-derived growth factor receptor-&#x003b2; desmin, calponin, &#x003b1;<italic toggle="yes">-</italic>smooth muscle actin, and VEGF receptor 2.&#x000a0;However, the endothelial cell or adipocyte markers, including CD31 and S-100, are not expressed.<xref ref-type="bibr" rid="article-17578.r40">[40]</xref></p>
        <p>Renal angiomyolipomas typically exhibit strong positive staining for estrogen, progesterone, and androgen receptors, partially explaining their increased incidence in females and the observed accelerated growth in patients undergoing hormonal therapy.<xref ref-type="bibr" rid="article-17578.r49">[49]</xref></p>
        <p>Melanocytic markers for spindle cells, such as HMB-45 and Melan-A, can help differentiate angiomyolipomas from various sarcomas.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r48">[48]</xref></p>
        <p>Malignant angiomyolipomas are extremely rare. Risk factors include lesions without fat on imaging, pure epithelioid histology, size exceeding 7 cm, and signs of intralesional necrosis.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r50">[50]</xref><xref ref-type="bibr" rid="article-17578.r51">[51]</xref></p>
      </sec>
      <sec id="article-17578.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Renal angiomyolipomas are mostly asymptomatic and typically diagnosed incidentally.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;The advancements in imaging technology have significantly increased the likelihood of diagnosing more cases.<xref ref-type="bibr" rid="article-17578.r44">[44]</xref>&#x000a0;</p>
        <p>Historically, up to 15% of patients have presented with spontaneous retroperitoneal hemorrhage, also known as Wunderlich syndrome, which can be severe and may result in shock in approximately one-third of cases.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Therefore, the primary clinical concern in patients newly diagnosed with renal angiomyolipoma is the risk of potentially life-threatening bleeding.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Although spontaneous retroperitoneal bleeding can also be caused by renal cancer or renal cystic disease, angiomyolipomas represent the most common etiology.</p>
        <p>Possible clinical signs and symptoms include flank pain, palpable abdominal mass, urinary tract infection, hematuria, anemia, severe renal insufficiency, and shock.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;Although&#x000a0;classic renal angiomyolipomas generally have a benign prognosis, the epithelioid variant can potentially undergo malignant transformation.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref></p>
        <p>Renal angiomyolipomas associated with&#x000a0;tuberous sclerosis complex or pulmonary lymphangioleiomyomatosis tend to be more aggressive. They typically manifest at an earlier age, are more likely to be bilateral and multifocal, and are larger at the time of initial diagnosis compared to the more common sporadic variety.<xref ref-type="bibr" rid="article-17578.r4">[4]</xref><xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r52">[52]</xref></p>
      </sec>
      <sec id="article-17578.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Renal angiomyolipomas can manifest as either fat-rich, fat-poor, or fat-invisible masses.<xref ref-type="bibr" rid="article-17578.r53">[53]</xref>&#x000a0;Approximately 5% of angiomyolipomas belong to the fat-poor or fat-invisible variety.<xref ref-type="bibr" rid="article-17578.r54">[54]</xref><xref ref-type="bibr" rid="article-17578.r55">[55]</xref><xref ref-type="bibr" rid="article-17578.r56">[56]</xref></p>
        <p>Computed tomography (CT) scanning is typically the initial imaging modality used, often performed for unrelated reasons, and may be adequate for diagnosis. If CT scanning is inconclusive or further characterization is needed, magnetic resonance imaging (MRI) is preferred as it is more sensitive in identifying fat-poor angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref><xref ref-type="bibr" rid="article-17578.r57">[57]</xref>&#x000a0;In addition, CT scans offer advantages such as widespread availability, lower cost, easier access, and rapid performance. However, for fat-invisible lesions, neither CT nor MRI may suffice, necessitating either a percutaneous biopsy or surgical intervention for accurate diagnosis.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref></p>
        <p>The cornerstone for identifying renal angiomyolipomas is diagnostic imaging. In most cases, a biopsy is not necessary for diagnosis, but it may be required to rule out malignancy in challenging or complex cases, such as fat-invisible renal mass lesions.</p>
        <p><bold>Imaging Modalities for Diagnosing Renal&#x000a0;Angiomyolipomas</bold>&#x000a0;</p>
        <p>Various imaging techniques aid in the diagnosis of this condition, as outlined below.</p>
        <p><bold>Ultrasonography:</bold>&#x000a0;A hyperechoic lesion accompanied by posterior acoustic shadowing is a typical feature of fat-rich angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref> Renal masses may present as isoechoic or hyperechoic, and up to 30% of smaller renal cell cancers can also exhibit hyperechogenicity.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref><xref ref-type="bibr" rid="article-17578.r58">[58]</xref>&#x000a0;The echogenicity of the lesion directly correlates with the total fat content.<xref ref-type="bibr" rid="article-17578.r31">[31]</xref> Fat-poor angiomyolipomas have a mixed echogenicity.<xref ref-type="bibr" rid="article-17578.r4">[4]</xref><xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Fat-invisible angiomyolipomas are homogeneously isoechoic.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;Unfortunately, approximately one-third of renal cell carcinomas can exhibit similar features on ultrasound.<xref ref-type="bibr" rid="article-17578.r58">[58]</xref> Consequently, the ultrasonographic findings in angiomyolipomas are frequently inconclusive, necessitating further investigations.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;The overall diagnostic accuracy of ultrasound in the initial diagnosis of angiomyolipomas is approximately 78%.<xref ref-type="bibr" rid="article-17578.r59">[59]</xref>&#x000a0;</p>
        <p>The combination of tumor size with ultrasonic image-based quantitative textural analysis improves the capability of ultrasonography to differentiate hyperechoic renal cell carcinomas from angiomyolipomas with increased accuracy.<xref ref-type="bibr" rid="article-17578.r60">[60]</xref>&#x000a0;Ultrasonography proves particularly valuable in monitoring the progression of known lesions, given its cost-effectiveness and minimal ionizing radiation exposure.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r61">[61]</xref></p>
        <p>If ultrasound reveals significant growth (&#x0003e;2.5 mm per year) or indicates a potentially serious change, it is advisable to proceed with a CT or MRI scan. Using the same imaging modality for tracking disease progression allows for more accurate comparisons over time. Therefore, a baseline ultrasound is advised for all newly diagnosed angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r60">[60]</xref></p>
        <p><bold>Computed tomography:&#x000a0;</bold>In CT scanning, the presence of a region of interest (ROI) exhibiting attenuations of &#x02212;10 Hounsfield units (HU) or less is considered a dependable and reliable indicator of fatty tissue, which is typically prominent in most fat-rich angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;However, CT scans may not depict a hypoattenuating area of less than &#x02212;10 HU in fat-poor angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r62">[62]</xref>&#x000a0;Thus, proper placement of the ROI is crucial for detecting the fatty tissue component of suspicious renal masses. Attenuation values will be higher if the ROI is positioned on the muscular or vascular component compared to when it is placed on fatty tissue.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;</p>
        <p>Fat-poor angiomyolipomas typically present as heterogeneously hyperattenuating or isoattenuating lesions. Conversely, fat-invisible angiomyolipomas demonstrate homogenously hyperattenuating characteristics due to the insufficient presence of adipose tissue, resulting in no density decrease. In such cases, an MRI is usually the next recommended imaging step. However, in selected cases where there is a high suspicion of active bleeding, a contrast-enhanced CT scan may be warranted to identify tortuous blood vessels prone to hemorrhage before considering therapeutic embolization.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref><xref ref-type="bibr" rid="article-17578.r63">[63]</xref></p>
        <p>In rare instances, renal cell carcinomas may exhibit hyperattenuation on CT (HU &#x0003c;&#x000a0;&#x02212;20), similar to renal angiomyolipomas. However, homogeneous lesion enhancement and prolonged enhancement patterns observed on biphasic helical CT scans can aid in distinguishing fat-poor AML from renal cell carcinoma. Additionally, the presence of calcification within the fat also favors renal cell carcinoma over renal angiomyolipoma.<xref ref-type="bibr" rid="article-17578.r64">[64]</xref></p>
        <p>The accuracy of detecting most renal angiomyolipomas is comparable between MRI and CT scans. However, MRI is deemed superior in detecting fat-poor lesions and is preferred in pediatric cases due to its avoidance of ionizing radiation. Children may require sedation during MRI scans due to extended study times.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref><xref ref-type="bibr" rid="article-17578.r65">[65]</xref>&#x000a0;</p>
        <p>In a study involving 98 pathologically confirmed fat-poor angiomyolipomas, 23% were detectable on MRI but not on CT scans.<xref ref-type="bibr" rid="article-17578.r66">[66]</xref>&#x000a0;The classical approach for diagnosing this condition involves identifying the fatty component within the mass.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref> The&#x000a0;most effective approach to locating the fatty area is comparing T1-weighted MRI images with and without selective fat suppression.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref></p>
        <p>Fat-rich angiomyolipomas typically exhibit T1 hypointensity (dark) with fat suppression and T1 and T2 hyperintensity (bright) without fat suppression. However, it is noteworthy that this T1 hyperintensity can also be observed in other conditions, such as renal cell carcinomas and hemorrhagic cysts, making it a non-specific or definitive diagnostic.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref>&#x000a0;</p>
        <p>On the other hand, fat-poor renal angiomyolipomas tend to appear heterogeneous or isointense to renal parenchyma. The primary diagnostic challenge lies in identifying a fat-invisible mass, which contains insufficient fat to demonstrate the hypointensity on fat-suppressed images necessary for diagnosis. Typically, these lesions appear homogeneously hypointense compared to the renal parenchyma due to their minimal fat content.<xref ref-type="bibr" rid="article-17578.r63">[63]</xref><xref ref-type="bibr" rid="article-17578.r67">[67]</xref>&#x000a0;</p>
        <p>Fat-invisible angiomyolipomas typically appear homogeneously hypointense on T2-weighted MRI images, whereas renal cell carcinomas, particularly the clear cell subtype, often present as hyperintense lesions.&#x000a0;Notably, papillary renal cell carcinoma can also manifest as a hypointense mass on T2-weighted images.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r66">[66]</xref>&#x000a0;</p>
        <p>The application of MRI artifacts has been proposed for improved evaluation of fat content in renal tumors. One such artifact is the India ink artifact, which creates a black line at the boundary between fat and water. Applying&#x000a0;this type of artifact can aid in diagnosing small tumors and fat-poor angiomyolipomas. Additionally, phase versus opposed-phase chemical shift MRI can help differentiate between fat-poor angiomyolipomas and renal cell carcinomas.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;</p>
        <p>Gadolinium contrast is generally unnecessary for diagnosis, but it can be useful in identifying internal aneurysms and assessing general vascularity. The reported overall sensitivity and specificity of MRI for diagnosing fat-poor angiomyolipomas are 83% and 90%, respectively.<xref ref-type="bibr" rid="article-17578.r57">[57]</xref>&#x000a0;In cases where MRI imaging fails to provide a definitive diagnosis, a biopsy may be required.</p>
        <p><bold>Percutaneous biopsy:&#x000a0;</bold>Percutaneous&#x000a0;renal biopsies are mainly indicated to differentiate malignant renal lesions from benign masses.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;As most renal masses show characteristic signs of malignancy and benign lesions, such as angiomyolipomas, which are usually diagnosed reliably with imaging, routine percutaneous biopsies are not generally necessary or recommended.&#x000a0;</p>
        <p>Lesions that&#x000a0;raise the suspicion of malignancy often exhibit necrosis, intralesional calcifications, or lymphadenopathy. In such cases, it is reasonable to proceed directly to surgical resection.<xref ref-type="bibr" rid="article-17578.r17">[17]</xref>&#x000a0;The primary objective of a percutaneous renal biopsy is to identify benign lesions that do not necessitate aggressive treatment, particularly in those rare equivocal cases where imaging modalities alone cannot provide a definitive diagnosis.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref><xref ref-type="bibr" rid="article-17578.r68">[68]</xref>&#x000a0; &#x000a0; &#x000a0;</p>
        <p>A percutaneous renal biopsy is usually reserved for cases where it is challenging to distinguish between a renal cell carcinoma and a fat-invisible or low-fat angiomyolipoma, particularly when both MRI and CT scan images are inconclusive or indecisive.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r69">[69]</xref>&#x000a0;Furthermore, a percutaneous renal biopsy may be necessary to differentiate between the papillary subtype of renal cell carcinoma and fat-invisible angiomyolipomas, especially if the lesion is small (&#x0003c;3 cm) and exhibits T2 hypointensity on MRI without any indication of fat within the tumor.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r68">[68]</xref>&#x000a0;If there is a high possibility of bleeding or the mass is particularly large, opting for appropriate surgical intervention upfront might be the preferable course of action to mitigate hemorrhagic complications.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref>&#x000a0;The risk of significant bleeding following a percutaneous biopsy in fat-invisible angiomyolipomas is no greater than for other renal masses.<xref ref-type="bibr" rid="article-17578.r70">[70]</xref></p>
        <p><bold>Renal nuclear scanning:</bold> Renal nuclear scanning with technetium-99m (Tc) mercapto-acetyl-triglycine (MAG3) renography is not generally used in the routine evaluation of angiomyolipomas and other renal masses.&#x000a0;However, it evaluates relative renal function, which can be helpful before nephron-sparing surgery. Furthermore, it may help differentiate renal masses and pseudomasses in cases where other imaging modalities are ambiguous.</p>
        <p>
<bold>Evaluation Summary</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Although ultrasonography can be useful for detecting or monitoring a renal mass, it is not considered reliable enough for an initial diagnosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CT scanning is generally the first line of approach in the initial evaluation of renal masses and is often sufficient for diagnostic information.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In cases where CT scans yield inconclusive results, MRI proves more sensitive, particularly for identifying fat-poor angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref><xref ref-type="bibr" rid="article-17578.r57">[57]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For certain fat-invisible lesions, no imaging modality offers a definitive diagnosis, necessitating either a percutaneous biopsy or direct surgical intervention.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If none of these methods can confidently diagnose the mass lesion, it should be managed as a renal malignancy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17578.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Indications for Treatment</bold>
</p>
        <p>Most angiomyolipoma cases are asymptomatic and usually do not require treatment, but therapeutic interventions are required in the minority of cases. In the past, the main indications for intervention included symptoms, suspicion of malignancy, presence of the tumor in women of childbearing age, and size larger than 4 cm.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref> However, recent studies challenge the historical 4 cm size threshold criterion, as only 30% of renal angiomyolipomas larger than 4 cm were symptomatic.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p>
        <p>Other studies revealed that using the 4 cm criterion as a predictor of hemorrhage has lower specificity than the tumoral aneurysmal diameter of larger than 5 mm.&#x000a0;The degree and complexity of the lesion's vascularity (multiple, large, tortuous vessels, aneurysms) is a better general indicator of the need for an intervention to prevent significant bleeding.<xref ref-type="bibr" rid="article-17578.r31">[31]</xref>&#x000a0;</p>
        <p>This evidence suggests that the vascularity of the angiomyolipoma and the size of any related aneurysms are ultimately more significant than the tumor size alone.<xref ref-type="bibr" rid="article-17578.r31">[31]</xref>&#x000a0;The average size of angiomyolipomas treated for bleeding is 7 cm, and recommendations for treatment based on tumor size range from 3 to 8 cm.<xref ref-type="bibr" rid="article-17578.r65">[65]</xref>&#x000a0;Using a&#x000a0;size criteria larger than 6 cm avoids presumed overtreatment in 65% of patients and is a reasonable compromise.<xref ref-type="bibr" rid="article-17578.r71">[71]</xref></p>
        <p>Additional high-risk factors for predicting bleeding from angiomyolipomas include an exophytic growth pattern, clinical symptoms (flank pain, nausea, and hematuria), female gender, age 15 to 50,&#x000a0;increased lesional vascularity, intralesional aneurysms larger than 5 mm in diameter, obesity, and the&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;genetic variant.<xref ref-type="bibr" rid="article-17578.r65">[65]</xref><xref ref-type="bibr" rid="article-17578.r71">[71]</xref><xref ref-type="bibr" rid="article-17578.r72">[72]</xref><xref ref-type="bibr" rid="article-17578.r73">[73]</xref><xref ref-type="bibr" rid="article-17578.r74">[74]</xref><xref ref-type="bibr" rid="article-17578.r75">[75]</xref></p>
        <p>During pregnancy, angiomyolipomas pose heightened concerns due to elevated estrogen receptor levels, leading to potential enlargement and a relatively high rate of reported hemorrhage.<xref ref-type="bibr" rid="article-17578.r76">[76]</xref><xref ref-type="bibr" rid="article-17578.r77">[77]</xref><xref ref-type="bibr" rid="article-17578.r78">[78]</xref>&#x000a0;If an angiomyolipoma is found in a pregnant female, management of these lesions should align with renal tumor protocols, emphasizing individualized treatment.<xref ref-type="bibr" rid="article-17578.r79">[79]</xref>&#x000a0;Recommendations from the European Association of Urology and the Canadian Best Practice Report advocate for considering and discussing angiomyolipoma treatment options with reproductive-age women diagnosed with these lesions.<xref ref-type="bibr" rid="article-17578.r76">[76]</xref><xref ref-type="bibr" rid="article-17578.r80">[80]</xref><xref ref-type="bibr" rid="article-17578.r81">[81]</xref></p>
        <p>Currently, the European Association of Urology, the Canadian Urological Association, and the International Consensus Statement from the European Rare Kidney Disease Reference Network (ERKNET) Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes &#x00026; Kidney Working Group concur that intervention should be considered in well-selected cases considering the following criteria:<xref ref-type="bibr" rid="article-17578.r13">[13]</xref><xref ref-type="bibr" rid="article-17578.r65">[65]</xref><xref ref-type="bibr" rid="article-17578.r80">[80]</xref><xref ref-type="bibr" rid="article-17578.r81">[81]</xref><xref ref-type="bibr" rid="article-17578.r82">[82]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Female patients requiring ongoing hormonal therapy</p>
          </list-item>
          <list-item>
            <p>individuals in high-risk occupations, such as commercial airline pilots</p>
          </list-item>
          <list-item>
            <p>Intralesional aneurysms larger than 5 mm</p>
          </list-item>
          <list-item>
            <p>Large lesions exceeding 6 cm (The European Consensus Guidelines recommend prophylactic embolization starting at 4 cm diameter)</p>
          </list-item>
          <list-item>
            <p>Lesions that are enlarging more than 2.5 mm per year (&#x0003e;5 mm yearly is considered high risk)</p>
          </list-item>
          <list-item>
            <p>Presence of multiple lesions</p>
          </list-item>
          <list-item>
            <p>Tumors in women of childbearing age&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Limited access to&#x000a0;emergency care or follow-up</p>
          </list-item>
          <list-item>
            <p>Poor patient compliance&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Symptomatic manifestations such as persistent pain</p>
          </list-item>
        </list>
        <p>Possible&#x000a0;interventions include medical treatment with mTOR inhibitors, thermal ablation methods such as radiofrequency ablation and cryotherapy, selective renal artery embolization, and surgical procedures, including total nephrectomy or partial nephron-sparing surgery.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref></p>
        <p><bold>Medical treatment:&#x000a0;</bold>Hereditary renal angiomyolipomas, linked with conditions such as tuberous sclerosis or pulmonary lymphangioleiomyomatosis, stem from mutations in the <italic toggle="yes">TSC1</italic> or <italic toggle="yes">TSC2</italic> genes, leading to uncontrolled activation of the mTOR pathway. This results in cell overgrowth and the formation of angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r11">[11]</xref><xref ref-type="bibr" rid="article-17578.r12">[12]</xref>&#x000a0;</p>
        <p>Medications that inhibit the mTOR pathway can&#x000a0;interrupt tumor progression and promote the reversion of the existing lesions.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r12">[12]</xref> Some recommendations suggested that all hereditary angiomyolipoma lesions 3 cm or larger be treated with mTOR inhibitor medications, even if asymptomatic.<xref ref-type="bibr" rid="article-17578.r1">[1]</xref><xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r83">[83]</xref></p>
        <p>The introduction of sirolimus marked the inception of mTOR inhibitor therapy used to treat hereditary angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r84">[84]</xref>&#x000a0;Initial studies with sirolimus showed a greater volume reduction in fat-poor lesions than in fat-rich angiomyolipomas. The reduction in excessive tumoral vascularity and associated aneurysms were markedly reduced by 75% to 100%, particularly notable in areas of the tumor with heightened vascularity and low-fat content.<xref ref-type="bibr" rid="article-17578.r85">[85]</xref></p>
        <p>Everolimus, also an mTOR inhibitor, is approved by the US Food and Drug Administration (FDA) for treating hereditary angiomyolipomas in tuberous sclerosis complex cases.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r28">[28]</xref><xref ref-type="bibr" rid="article-17578.r83">[83]</xref><xref ref-type="bibr" rid="article-17578.r86">[86]</xref>&#x000a0;Everolimus has been reported to reduce tumor size by an average of 55%.<xref ref-type="bibr" rid="article-17578.r87">[87]</xref>&#x000a0;The standard starting dosage of everolimus is 10 mg daily. Continued efficacy has been reported, even after 4 years of treatment.<xref ref-type="bibr" rid="article-17578.r88">[88]</xref></p>
        <p>After 6 months of standard everolimus therapy, patients with at least a 50% reduction may transition to a low daily dose of 5 mg everolimus. This adjustment aims to minimize adverse effects while effectively managing angiomyolipoma growth.<xref ref-type="bibr" rid="article-17578.r89">[89]</xref>&#x000a0;Patients who fail to meet this requirement remain on the standard 10 mg daily dosage of everolimus for an additional 6 months before transitioning to the lower dosage, regardless of their response.<xref ref-type="bibr" rid="article-17578.r89">[89]</xref>&#x000a0;This decision was based on research indicating that angiomyolipoma tumor size stabilizes six months after initiating everolimus therapy. This stabilization effect parallels those observed in patients with tuberous sclerosis and subependymal giant cell astrocytomas.<xref ref-type="bibr" rid="article-17578.r83">[83]</xref><xref ref-type="bibr" rid="article-17578.r90">[90]</xref><xref ref-type="bibr" rid="article-17578.r91">[91]</xref></p>
        <p>Intermittent everolimus therapy for controlling angiomyolipomas in tuberous sclerosis patients has been explored. Approximately 30% of participants in a study experienced angiomyolipoma stabilization upon everolimus withdrawal.<xref ref-type="bibr" rid="article-17578.r92">[92]</xref> The remainder had to resume everolimus, and all responded with a significant reduction in angiomyolipoma tumor size, similar to the initial response.<xref ref-type="bibr" rid="article-17578.r92">[92]</xref></p>
        <p>Using everolimus for sporadic angiomyolipomas poses challenges. A 2020 phase II multi-institutional prospective trial showed promising efficacy in patients with 4 to 6 cycles of monthly everolimus therapy&#x000a0;based on response and tolerability.<xref ref-type="bibr" rid="article-17578.r83">[83]</xref> Over 50% of patients experienced a tumor size reduction of 25% or more, but nearly 50% faced adverse effects or toxicities that required modification or discontinuation of therapy.<xref ref-type="bibr" rid="article-17578.r86">[86]</xref>&#x000a0;This compares favorably with the EXIST-2 trial findings of everolimus use in hereditary angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r83">[83]</xref></p>
        <p>Medical therapy of angiomyolipomas is preferred over surgical management, whenever possible, to preserve renal function.<xref ref-type="bibr" rid="article-17578.r65">[65]</xref><xref ref-type="bibr" rid="article-17578.r93">[93]</xref> Although mTOR inhibitors are preferred, they carry risks of adverse effects, sometimes necessitating dose adjustment or discontinuation if the patient manifests severe adverse effects.<xref ref-type="bibr" rid="article-17578.r94">[94]</xref>&#x000a0;The most common adverse effects of these medications include amenorrhea, delayed wound healing, dyslipidemia, fatigue, hyperglycemia, hypophosphatemia, infections, lymphopenia, microcytic anemia, non-infectious pneumonitis, proteinuria, stomatitis, and thrombocytopenia.<xref ref-type="bibr" rid="article-17578.r14">[14]</xref></p>
        <p><bold>Thermal ablative therapy:</bold> Thermal ablative therapy, including radiofrequency ablation and cryotherapy, has been recommended by the American Urological Association Guidelines for treating small renal masses (&#x0003c;3 cm).<xref ref-type="bibr" rid="article-17578.r82">[82]</xref><xref ref-type="bibr" rid="article-17578.r95">[95]</xref>&#x000a0;</p>
        <p>Specific selection depends on patient characteristics, tumor size, location, local experience, and expertise. Thermal ablative therapies, such as cryotherapy and radiofrequency ablation, offer the advantage of being performed simultaneously with percutaneous renal biopsies and effectiveness regardless of tumor characteristics. However, selective angiographic embolization, requiring a clear diagnosis before treatment, remains the preferred minimally invasive procedure for angiomyolipomas.<xref ref-type="bibr" rid="article-17578.r82">[82]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Cryotherapy: Cryotherapy has demonstrated success in a limited number of angiomyolipoma cases, yet routine recommendation lacks sufficient reported data.<xref ref-type="bibr" rid="article-17578.r31">[31]</xref><xref ref-type="bibr" rid="article-17578.r95">[95]</xref><xref ref-type="bibr" rid="article-17578.r96">[96]</xref><xref ref-type="bibr" rid="article-17578.r97">[97]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>Cryotherapy has some unique advantages, including minimal damage to surrounding renal tissue, a well-defined area of ablation, the ability to obtain a tissue biopsy during the same procedure, percutaneous accessibility, minimally invasive technology, and the delivery of definitive treatment to the mass regardless of whether it is eventually determined to be a benign or malignant lesion.</p></list-item><list-item><p>Cryotherapy may be a reasonable option in institutions experienced with this modality. This is especially true when arterial embolization has failed or is not technically feasible. Cryotherapy is also suitable when minimal loss of renal function is desired or when diagnostic uncertainty exists. Additionally, it is an alternative to surgical resection for patients with preexisting renal failure or extensive bilateral disease.</p></list-item><list-item><p>Participation in a clinical trial is advisable when contemplating renal cryoablation. While no data exist on combining angiographic embolization with renal cryotherapy, it could theoretically offer superior outcomes for larger tumors.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Radiofrequency ablation: Radiofrequency ablation of angiomyolipomas has shown minimal complications and good efficacy. This minimally invasive technique is ideal for small-sized asymptomatic tumors but can also target large masses.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>Radiofrequency ablation targets the vascular and solid elements of the tumor mass without damaging normal renal tissue. Studies evaluating its efficacy for small renal angiomyolipomas have been conducted in relatively small series.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p></list-item><list-item><p>In a study involving 15 small renal angiomyolipomas, successful treatment resulted in the complete disappearance of tumoral enhancement on CT scan, with a low complication rate (13%) observed at a mean follow-up of 21 months.<xref ref-type="bibr" rid="article-17578.r98">[98]</xref>&#x000a0;</p></list-item><list-item><p>In another study, radiofrequency ablation of a sporadic angiomyolipoma in a patient with a solitary kidney resulted in a reduction in tumor size from 4.5 cm to 2.9 cm. Also, no complications or tumor recurrence were observed at the 12-month follow-up.<xref ref-type="bibr" rid="article-17578.r99">[99]</xref><xref ref-type="bibr" rid="article-17578.r100">[100]</xref>&#x000a0;</p></list-item><list-item><p>A separate study used radiofrequency ablation to treat 4 large angiomyolipomas without any reported complications or hemorrhagic events. Over a 48-month follow-up period, the study demonstrated a significant decrease in the mean soft-tissue-to-total tumor ratio, although the total tumor volume did not significantly change.<xref ref-type="bibr" rid="article-17578.r100">[100]</xref><xref ref-type="bibr" rid="article-17578.r101">[101]</xref>&#x000a0;</p></list-item><list-item><p>CT scans usually guide the procedure, but ultrasonography is a possible alternative.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p></list-item><list-item><p>CT scan guidance becomes necessary for tumors that are not easily and safely targeted by ultrasonography. Numerous studies have shown that combining superselective renal artery embolization with radiofrequency ablation yields excellent success rates.<xref ref-type="bibr" rid="article-17578.r102">[102]</xref>&#x000a0;Further studies are needed to determine whether this approach offers superior long-term outcomes compared to alternative treatment.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Selective renal artery embolization:&#x000a0;</bold>In the past, the main treatment for angiomyolipoma was surgical excision&#x000a0;because tumor malignancy could not be excluded.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref><xref ref-type="bibr" rid="article-17578.r16">[16]</xref>&#x000a0;Currently, selective renal artery embolization is considered the first-line treatment for angiomyolipoma, particularly in cases at risk of acute bleeding, active hemorrhaging, or hemodynamic instability.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r14">[14]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref><xref ref-type="bibr" rid="article-17578.r80">[80]</xref><xref ref-type="bibr" rid="article-17578.r82">[82]</xref><xref ref-type="bibr" rid="article-17578.r103">[103]</xref>&#x000a0;</p>
        <p>Selective renal artery embolization is the preferred procedural option, with surgery and thermal ablative therapies considered for cases with vascular malformations, uncontrollable symptoms, embolization failures, or diagnostic uncertainty. This approach boasts an impressive success rate of 93%, with an average reduction in tumor size of 38%.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r14">[14]</xref></p>
        <p>When the surgical option is indicated, preoperative embolization of the tumor may be considered to reduce the complications and the difficulty of the operation.<xref ref-type="bibr" rid="article-17578.r4">[4]</xref><xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref>&#x000a0;However, embolization is not a risk-free option and is associated with a relatively high rate of adverse effects (43%).<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Most of these adverse effects are related to a post-embolization syndrome&#x000a0;characterized by&#x000a0;flank pain, fever, vomiting, nausea, and&#x000a0;leukocytosis during the first 3 days after the procedure.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r16">[16]</xref>&#x000a0;</p>
        <p>These adverse effects are generally managed conservatively with standard supportive care. Prescribing&#x000a0;antipyretics, antiemetics, and analgesia prophylactically could significantly minimize and control these symptoms.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r80">[80]</xref> Despite this, up to 30% of cases undergoing selective arterial embolization may require a second treatment primarily due to tumor revascularization.<xref ref-type="bibr" rid="article-17578.r14">[14]</xref><xref ref-type="bibr" rid="article-17578.r81">[81]</xref></p>
        <p><bold>Surgical excision:&#x000a0;</bold>Surgical excision, whether total or partial nephrectomy, remains the definitive treatment option for completely eradicating the renal mass.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref>&#x000a0;Every surgical operation should use a nephron-sparing approach whenever possible.<xref ref-type="bibr" rid="article-17578.r3">[3]</xref><xref ref-type="bibr" rid="article-17578.r14">[14]</xref><xref ref-type="bibr" rid="article-17578.r82">[82]</xref>&#x000a0;Preserving renal parenchyma is particularly crucial in patients with hereditary angiomyolipomas due to their elevated recurrence rate, accelerated growth, and multifocal disease pattern.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p>
        <p>Nephrectomy is usually indicated when the suspicion of malignancy is high, the renal mass is particularly large, or other treatment modalities cannot be performed.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;However, in an emergency, a nephrectomy can be a lifesaving option.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r11">[11]</xref><xref ref-type="bibr" rid="article-17578.r104">[104]</xref>&#x000a0;Surgical excision offers the advantage of a higher cure rate and requires fewer follow-up procedures, resulting in reduced surveillance compared to arterial embolization.</p>
        <p>
<bold>Active Surveillance and Follow-Up</bold>
</p>
        <p>Active surveillance is generally used to monitor the progression of existing tumors and the emergence of new ones when treatment indications are absent, following the completion of diagnostic evaluations.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r43">[43]</xref>&#x000a0;Given the low overall rate of spontaneous bleeding from angiomyolipomas (only 2%), surveillance is considered reasonable in most cases.<xref ref-type="bibr" rid="article-17578.r81">[81]</xref>&#x000a0;Currently, definitive guidelines do not exist for sporadic angiomyolipomas in terms of frequency or modality of imaging studies.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r31">[31]</xref>&#x000a0;Decisions should be guided according to the individual clinical scenario and history.<xref ref-type="bibr" rid="article-17578.r31">[31]</xref><xref ref-type="bibr" rid="article-17578.r105">[105]</xref>&#x000a0;</p>
        <p>An annual repeat of imaging may be appropriate for small and solitary lesions.<xref ref-type="bibr" rid="article-17578.r6">[6]</xref> For hereditary tumors (associated with tuberous sclerosis or lymphangioleiomyomatosis), multiple, bilateral, and larger lesions, biannual (twice annual) imaging is generally recommended at least initially, as some have been found to grow up to 1.5 cm a year.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref><xref ref-type="bibr" rid="article-17578.r106">[106]</xref></p>
        <p>For hereditary angiomyolipomas, the International Tuberous Sclerosis Complex Consensus highly recommends using a yearly MRI to monitor the condition due to its higher sensitivity in detecting adipose tissue.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Most published protocols start with biannual imaging, which may be modified to annual screenings if there is little change.<xref ref-type="bibr" rid="article-17578.r43">[43]</xref>&#x000a0;In these cases, blood pressure and renal function should be checked at least annually.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p>
        <p>Ultrasound is usually adequate for monitoring, with a CT scan or MRI reserved for significant changes. Avoiding routine CT scanning to minimize radiation exposure is advisable for long-term follow-up.</p>
        <p>
<bold>Treatment Summary</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Most angiomyolipomas can be managed without treatment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment considerations include current symptoms, size (&#x0003e;6 cm), growth rate (&#x0003e;2.5 mm per year), intratumoral aneurysms (&#x0003e;5 mm), high-risk scenarios, and potential lack of access to healthcare.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The least invasive treatment modality should be used whenever possible, which minimizes complications and loss of renal function.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sirolimus and everolimus have demonstrated efficacy in controlling renal tumor growth and inducing shrinkage in hereditary angiomyolipomas. Their effectiveness in sporadic angiomyolipomas is less established, but early studies suggest it can be effective.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Everolimus carries a high cost and notable adverse effects. Utilizing intermittent treatment and low-dose maintenance protocols can mitigate these challenges and minimize the negative aspects of everolimus administration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thermal therapies such as radiofrequency ablation and cryotherapy offer simultaneous percutaneous biopsies and efficacy across benign and malignant lesions. Their consideration for smaller tumors (&#x0003c;3 cm) should align with local expertise and availability.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Selective angiographic embolization is the preferred treatment for managing active bleeding and preventing high-risk angiomyolipomas. Despite its effectiveness, it comes with a high retreatment rate of 30% and necessitates a confirmed diagnosis before therapy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Surgery is the most definitive curative therapy but is reserved for situations that cannot be better managed with less invasive modalities or require urgent resolution. Nephron-sparing minimally invasive techniques are advocated as the preferred approach.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17578.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Recognizing the various types of renal angiomyolipomas, including fat-rich, fat-poor, and fat-invisible variants, is crucial.<xref ref-type="bibr" rid="article-17578.r31">[31]</xref> Fat-rich angiomyolipomas are diagnosed easily on imaging due to the high amount of adipose tissue in the mass. However, accurately diagnosing renal angiomyolipomas with poor or no fat visualization presents a primary challenge.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p>
        <p>Before initiating treatment, it is crucial to rule out other potential differential diagnoses.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref> The possible differential diagnoses of renal angiomyolipoma include adrenal myelolipoma, oncocytoma, renal cell carcinoma, retroperitoneal liposarcoma, tumors metastatic to the kidney, and Wilms tumor.<xref ref-type="bibr" rid="article-17578.r107">[107]</xref><xref ref-type="bibr" rid="article-17578.r108">[108]</xref></p>
        <p>The widespread adoption of high-resolution imaging techniques has increased the&#x000a0;detection of small renal masses. Often discovered incidentally, many of&#x000a0;these small renal lesions&#x000a0;are suspected of possible renal cell carcinomas and managed accordingly. However, approximately 22% of these masses are later determined benign after surgical excision, with renal angiomyolipomas comprising roughly half of these cases.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p>
        <p>Differentiating between renal cell carcinomas and angiomyolipomas can pose challenges in routine clinical practice.<xref ref-type="bibr" rid="article-17578.r62">[62]</xref><xref ref-type="bibr" rid="article-17578.r109">[109]</xref><xref ref-type="bibr" rid="article-17578.r110">[110]</xref>&#x000a0;A&#x000a0;primary diagnostic challenge lies in differentiating fat-poor or fat-invisible angiomyolipomas from renal cell carcinomas.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;</p>
        <p>Clinical information that favors the diagnosis of angiomyolipoma includes female gender, younger age, and asymptomatic clinical manifestations.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Imaging results&#x000a0;that raise suspicion of angiomyolipoma include the presence of multiple lesions, absence of calcifications, T2-weighted hypointensity on MRI, and hyperattenuation on CT scans.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref> However, it is&#x000a0;noteworthy that exceptions exist, and no single clinical finding or imaging modality is definitive in all cases.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r111">[111]</xref><xref ref-type="bibr" rid="article-17578.r112">[112]</xref><xref ref-type="bibr" rid="article-17578.r113">[113]</xref></p>
        <p>Retroperitoneal liposarcomas may also appear similar to larger angiomyolipomas. However, as angiomyolipomas are renal parenchymal tumors, they typically present with an indentation or dimple at the site of origin. In contrast, liposarcoma tends to envelop and compress the entire kidney without a distinct originating marker.<xref ref-type="bibr" rid="article-17578.r114">[114]</xref><xref ref-type="bibr" rid="article-17578.r115">[115]</xref></p>
        <p>Although some angiomyolipomas can grow rapidly, the majority exhibit slow growth. Rapid enlargement (&#x0003e;5 mm per year) should raise suspicion of potential malignancy.<xref ref-type="bibr" rid="article-17578.r65">[65]</xref><xref ref-type="bibr" rid="article-17578.r116">[116]</xref><xref ref-type="bibr" rid="article-17578.r117">[117]</xref><xref ref-type="bibr" rid="article-17578.r118">[118]</xref>&#x000a0;Failure of a lesion to respond to mTOR inhibitors is also considered suspicious.<xref ref-type="bibr" rid="article-17578.r65">[65]</xref><xref ref-type="bibr" rid="article-17578.r119">[119]</xref> Suspected malignant lesions, characterized by features such as tumoral necrosis or internal calcifications, regional lymphadenopathy, metastasis, or perinephric extension, typically warrant surgical intervention unless definitively determined to be benign by a percutaneous biopsy.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r6">[6]</xref><xref ref-type="bibr" rid="article-17578.r17">[17]</xref><xref ref-type="bibr" rid="article-17578.r69">[69]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17578.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Small angiomyolipomas and those lacking aneurysms usually carry a favorable prognosis due to a low risk of spontaneous bleeding, estimated at only 2%.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r81">[81]</xref>&#x000a0; However, renal angiomyolipomas harboring aneurysms larger than 5 mm or exhibiting a size exceeding 6 cm present a considerable risk of spontaneous rupture and hemorrhage, constituting a life-threatening&#x000a0;condition.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref><xref ref-type="bibr" rid="article-17578.r120">[120]</xref>&#x000a0;Additionally, the malignant potential of certain angiomyolipoma types serves as another crucial prognostic factor, as they may have a greater tendency for this transformation.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref> &#x000a0;</p>
        <p>Updated clinical guidelines are essential to assist physicians in determining optimal management strategies for these rare and atypical cases. Progress in treatments or potential cures will necessitate ongoing translational research in genomics, immunotherapy, and other emerging treatment modalities.<xref ref-type="bibr" rid="article-17578.r121">[121]</xref></p>
      </sec>
      <sec id="article-17578.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Although renal angiomyolipoma is a rare benign neoplasm, it may still impose significant morbidity and mortality due to the tumor's unique vascular characteristics and the possible complications associated with treatment.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref></p>
        <p>The risk of bleeding associated with renal angiomyolipomas is a challenging factor.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Studies have consistently shown that large tumors (&#x0003e;6 cm) and lesions associated with tuberous sclerosis complex are considered more susceptible to bleeding than small sporadic lesions, highlighting the importance of prophylactic treatment.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref>&#x000a0;</p>
        <p>Another important complication associated with renal angiomyolipomas is the potential for renal impairment over time.<xref ref-type="bibr" rid="article-17578.r11">[11]</xref></p>
      </sec>
      <sec id="article-17578.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>The management of renal angiomyolipoma and its complications requires a multidisciplinary team, which can include specialists from various fields such as general surgery, genetics, interventional radiology, nephrology, oncology, pathology, primary care, radiology, urology, and vascular surgery.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref></p>
      </sec>
      <sec id="article-17578.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with renal angiomyolipoma should be informed about the generally benign nature of the disease.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Healthcare professionals should clarify that available medications and minimally invasive treatments can help halt the disease's progression and reduce the risk of spontaneous bleeding.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref>&#x000a0;Healthcare providers must also advise patients about the importance of medication adherence and compliance, as well as the need for long-term surveillance.<xref ref-type="bibr" rid="article-17578.r16">[16]</xref>&#x000a0;</p>
        <p>Any woman of childbearing age diagnosed with renal angiomyolipoma who plans to become pregnant should seek consultation to discuss the management of their condition before and during pregnancy. Pregnancy is considered a significant risk factor for disease progression and complications, as the tumor mass is likely to grow and may rupture during pregnancy.<xref ref-type="bibr" rid="article-17578.r5">[5]</xref><xref ref-type="bibr" rid="article-17578.r11">[11]</xref></p>
      </sec>
      <sec id="article-17578.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Many experts recommend that all patients with newly diagnosed angiomyolipomas be evaluated for tuberous sclerosis.
<list list-type="bullet"><list-item><p>Conversely, all patients with tuberous sclerosis should be screened for angiomyolipomas.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal imaging for angiomyolipomas is advised for all patients with lymphangioleiomyomatosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Asymptomatic patients with lesions&#x000a0;smaller than 4 cm are unlikely to have tuberous sclerosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Selective angiographic embolization is the preferred method for controlling active bleeding, although there is a 30% retreatment rate.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Biopsy should be considered if the diagnosis cannot be conclusively made from CT and MRI scans alone.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Therapy with the mTOR inhibitors, such as sirolimus and everolimus, should be considered for lesions 3 cm or larger.<xref ref-type="bibr" rid="article-17578.r122">[122]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intermittent mTOR therapy and low-dose maintenance treatment protocols can help mitigate adverse effects and lower medication costs.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Medical therapy is generally preferred over surgical procedures whenever possible.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MRI imaging, being more sensitive to detecting fat than CT scans, is particularly valuable for identifying fat-poor lesions. Imaging fat-invisible lesions can pose challenges.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Over 90% of all angiomyolipomas do not require treatment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prophylactic surgical treatment is recommended for angiomyolipomas larger than 6 cm or those with intralesional aneurysms larger than 5 mm.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The risk associated with percutaneous biopsy is not higher for patients with low-fat or invisible-fat angiomyolipomas compared to other renal tumors.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Surgical intervention, employing minimally invasive ablative technologies and nephron-sparing techniques, should be pursued whenever feasible.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ultrasound is not sufficiently detailed to definitively diagnose angiomyolipomas but can track previously identified lesions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If all diagnostic measures have failed to confirm a reliable diagnosis, treating the lesion as malignant is advisable.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In cases where a renal mass lesion cannot be definitively identified as an angiomyolipoma from imaging alone but is suspected to be one, a percutaneous biopsy is a reasonable option, particularly for high-risk patients, as it may help avoid potential surgical complications.<xref ref-type="bibr" rid="article-17578.r69">[69]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Women of childbearing age should consider prophylactic treatment for angiomyolipomas due to the elevated risk of complications during pregnancy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17578.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing renal angiomyolipoma requires the collaboration of the entire interprofessional healthcare team. The primary healthcare provider may be the first to encounter the initial symptomatic presentation of the disease. Radiologists and interventional radiologists are crucial in confirming the diagnosis and monitoring disease progression through imaging. In some cases, a percutaneous renal biopsy may be necessary to confirm the diagnosis.&#x000a0;</p>
        <p>All medical efforts should prioritize preserving renal function while preventing disease progression and associated complications. Whenever feasible, medical therapy is preferred over nephron-sparing surgeries. Additionally, as detailed previously, other specialists may be consulted to provide expertise on the case.</p>
        <p>The nursing staff are critical&#x000a0;in patient counseling, surgical assistance, and coordination of interventions between specialties. They also play a vital role in notifying the relevant clinicians of any changes in patient clinical status and addressing patient inquiries. If medical therapy is included in the treatment plan, pharmacists can provide counseling on appropriate dosing and administration, conduct medication reconciliation, and communicate with the prescribing clinician regarding any medication-related concerns.</p>
        <p>All interprofessional healthcare team members should meticulously document their activities and interventions in the patient's medical record so that all team members have access to the same up-to-date, accurate information. Open communication among healthcare team members is essential for discussing the case and implementing the best therapeutic options. This collaborative approach ensures optimal patient outcomes.</p>
      </sec>
      <sec id="article-17578.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17578&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17578">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/renal-angiomyolipoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17578">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17578/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17578">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17578.s18">
        <fig id="article-17578.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Histology, Renal Angiomyolipoma Contributed by D Kabir MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_Angiomyolipoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17578.s19">
        <title>References</title>
        <ref id="article-17578.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Egawa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.</article-title>
            <source>Asian J Surg</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>967</fpage>
            <page-range>967-972</page-range>
            <pub-id pub-id-type="pmid">31959574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Thani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>El-Menyar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Sulaiti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El-Mabrok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hajaji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Elgohary</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Al-Malki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabeb</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation, management, and outcome of patients with incidental renal angiomyolipoma in qatar.</article-title>
            <source>Oman Med J</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>419</fpage>
            <page-range>419-24</page-range>
            <pub-id pub-id-type="pmid">25584159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lane</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Danforth</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Remer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Novick</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid.</article-title>
            <source>J Urol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>180</volume>
            <issue>3</issue>
            <fpage>836</fpage>
            <page-range>836-43</page-range>
            <pub-id pub-id-type="pmid">18635231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halpenny</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Snow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McNeill</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Torreggiani</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>The radiological diagnosis and treatment of renal angiomyolipoma-current status.</article-title>
            <source>Clin Radiol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-108</page-range>
            <pub-id pub-id-type="pmid">20103431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oyen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Renal Angiomyolipoma: The Good, the Bad, and the Ugly.</article-title>
            <source>J Belg Soc Radiol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>20</day>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">30039053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jinzaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Akita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagashima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mikami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oya</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management.</article-title>
            <source>Abdom Imaging</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>588</fpage>
            <page-range>588-604</page-range>
            <pub-id pub-id-type="pmid">24504542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minja</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Pellerin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saviano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Retroperitoneal extrarenal angiomyolipomas: an evidence-based approach to a rare clinical entity.</article-title>
            <source>Case Rep Nephrol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>374107</fpage>
            <pub-id pub-id-type="pmid">24555133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Right renal angiomyolipoma with intracardiac extension and pulmonary embolism.</article-title>
            <source>J Clin Ultrasound</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>516</fpage>
            <page-range>516-519</page-range>
            <pub-id pub-id-type="pmid">33325037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouaziz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghalleb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tounsi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Riahi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bouzaiene</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ziadi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hassouna</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Slimane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rahal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A renal angiomyolipoma with a challenging presentation: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2021</year>
            <month>Sep</month>
            <day>27</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>477</fpage>
            <pub-id pub-id-type="pmid">34565446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Primary kidney malignant epithelioid angiomyolipoma: Two cases report and review of literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>97</volume>
            <issue>32</issue>
            <fpage>e11805</fpage>
            <pub-id pub-id-type="pmid">30095646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seyam</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Alkhudair</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alotaibi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Altaweel</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>The Risks of Renal Angiomyolipoma: Reviewing the Evidence.</article-title>
            <source>J Kidney Cancer VHL</source>
            <year>2017</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>13</fpage>
            <page-range>13-25</page-range>
            <pub-id pub-id-type="pmid">29090118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A Multi-Centric Study Assessing Safety and Efficacy of Everolimus in Adult Chinese Patients With Tuberous Sclerosis Complex Associated Renal Angiomyolipomas.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>871723</fpage>
            <pub-id pub-id-type="pmid">35860575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Finelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manickavachagam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Legere</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sykes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jhaveri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jewett</surname>
                <given-names>MAS</given-names>
              </name>
            </person-group>
            <article-title>Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs &#x0003e;4cm Can Be Offered Active Surveillance as an Initial Management Strategy.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-90</page-range>
            <pub-id pub-id-type="pmid">26873836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ariceta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buj</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Furlano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Matamala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robles</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Sans</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Villacampa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for the management of renal involvement in the tuberous sclerosis complex.</article-title>
            <source>Nefrologia (Engl Ed)</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-151</page-range>
            <pub-id pub-id-type="pmid">31722796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Tuberous Sclerosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">30860727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flum</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hamoui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Casalino</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Nadler</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Update on the Diagnosis and Management of Renal Angiomyolipoma.</article-title>
            <source>J Urol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>195</volume>
            <issue>4 Pt 1</issue>
            <fpage>834</fpage>
            <page-range>834-46</page-range>
            <pub-id pub-id-type="pmid">26612197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sooriakumaran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coughlin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Attard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Elmslie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corbishley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated.</article-title>
            <source>BJU Int</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>105</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-6</page-range>
            <pub-id pub-id-type="pmid">19493268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seyam</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bissada</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mokhtar</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Aslam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fahmy</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Mourad</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Binmahfouz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hanash</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms.</article-title>
            <source>Urology</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>1077</fpage>
            <page-range>1077-82</page-range>
            <pub-id pub-id-type="pmid">18805573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aydin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Magi-Galluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Sercia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Rini</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>289</fpage>
            <page-range>289-97</page-range>
            <pub-id pub-id-type="pmid">18852677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bombardieri</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tuberous sclerosis.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2008</year>
            <volume>87</volume>
            <fpage>129</fpage>
            <page-range>129-51</page-range>
            <pub-id pub-id-type="pmid">18809023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>1181</fpage>
            <page-range>1181-92</page-range>
            <pub-id pub-id-type="pmid">21916571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harknett</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Byrnes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lazor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geiling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Telford</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tattersfield</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis.</article-title>
            <source>QJM</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>104</volume>
            <issue>11</issue>
            <fpage>971</fpage>
            <page-range>971-9</page-range>
            <pub-id pub-id-type="pmid">21764810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khaddour</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sankari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shayuk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Lymphangioleiomyomatosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">30480964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ruoss</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Raffin</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Peavy</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taveira-Dasilva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Avila</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Decastro</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Stylianou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fanburg</surname>
                <given-names>BL</given-names>
              </name>
              <collab>NHLBI LAM Registry Group</collab>
            </person-group>
            <article-title>The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>173</volume>
            <issue>1</issue>
            <fpage>105</fpage>
            <page-range>105-11</page-range>
            <pub-id pub-id-type="pmid">16210669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Newell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Adamczyk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mortenson</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>152</volume>
            <issue>6 Pt 1</issue>
            <fpage>2138</fpage>
            <page-range>2138-43</page-range>
            <pub-id pub-id-type="pmid">8520787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Taveira-DaSilva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Glasgow</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Steagall</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sahn</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kotloff</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>D'Armiento</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Kinder</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Wikenheiser-Brokamp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cordier</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <collab>ATS/JRS Committee on Lymphangioleiomyomatosis</collab>
            </person-group>
            <article-title>Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2016</year>
            <month>Sep</month>
            <day>15</day>
            <volume>194</volume>
            <issue>6</issue>
            <fpage>748</fpage>
            <page-range>748-61</page-range>
            <pub-id pub-id-type="pmid">27628078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Contemporary diagnosis and management of renal angiomyolipoma.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>168</volume>
            <issue>4 Pt 1</issue>
            <fpage>1315</fpage>
            <page-range>1315-25</page-range>
            <pub-id pub-id-type="pmid">12352384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review.</article-title>
            <source>Ther Adv Urol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-290</page-range>
            <pub-id pub-id-type="pmid">27928430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ajima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tosaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takehara</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Benign renal tumors detected among healthy adults by abdominal ultrasonography.</article-title>
            <source>Eur Urol</source>
            <year>1995</year>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-7</page-range>
            <pub-id pub-id-type="pmid">7744154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rule</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Sasiwimonphan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lieske</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Keddis</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Vrtiska</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2012</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>611</fpage>
            <page-range>611-8</page-range>
            <pub-id pub-id-type="pmid">22398108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiefer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Stavropoulos</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>The Role of Interventional Radiology Techniques in the Management of Renal Angiomyolipomas.</article-title>
            <source>Curr Urol Rep</source>
            <year>2017</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">28299630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma and massive retroperitoneal hemorrhage during pregnancy.</article-title>
            <source>West J Med</source>
            <year>1985</year>
            <month>Nov</month>
            <volume>143</volume>
            <issue>5</issue>
            <fpage>675</fpage>
            <page-range>675-6</page-range>
            <pub-id pub-id-type="pmid">4082575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petrikovsky</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Vintzileos</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cassidy</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Tuberous sclerosis in pregnancy.</article-title>
            <source>Am J Perinatol</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-5</page-range>
            <pub-id pub-id-type="pmid">2184812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lalot</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Meistelman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Longrois</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Renal angiomyolipoma rupture during pregnancy].</article-title>
            <source>Gynecol Obstet Fertil</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>917</fpage>
            <page-range>917-9</page-range>
            <pub-id pub-id-type="pmid">16996772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zapardiel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Delafuente-Valero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bajo-Arenas</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma during pregnancy: review of the literature.</article-title>
            <source>Gynecol Obstet Invest</source>
            <year>2011</year>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>217</fpage>
            <page-range>217-9</page-range>
            <pub-id pub-id-type="pmid">21876331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gould Rothberg</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Grooms</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Dharnidharka</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>108</volume>
            <issue>3 Pt 2</issue>
            <fpage>734</fpage>
            <page-range>734-6</page-range>
            <pub-id pub-id-type="pmid">17018483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benedik</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D' Amato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>d'Aug&#x000e8;res</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Feucht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fladrowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Macaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Touraine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Youroukos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>502</fpage>
            <page-range>502-508</page-range>
            <pub-id pub-id-type="pmid">29697822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachour</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>House</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Debicki</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Desbiens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fantaneanu</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kyriakopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lattouf</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Suller-Marti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Keezer</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Adults with tuberous sclerosis complex: A distinct patient population.</article-title>
            <source>Epilepsia</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>663</fpage>
            <page-range>663-671</page-range>
            <pub-id pub-id-type="pmid">34967000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ewalt</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Sheffield</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sparagana</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Roach</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Renal lesion growth in children with tuberous sclerosis complex.</article-title>
            <source>J Urol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>160</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-5</page-range>
            <pub-id pub-id-type="pmid">9628635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siroky</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Reichert</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hellmann</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ramkumar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsuchihashi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bunni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>01</day>
            <volume>307</volume>
            <issue>5</issue>
            <fpage>F560</fpage>
            <page-range>F560-70</page-range>
            <pub-id pub-id-type="pmid">24920756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karbowniczek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures.</article-title>
            <source>Am J Pathol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>162</volume>
            <issue>2</issue>
            <fpage>491</fpage>
            <page-range>491-500</page-range>
            <pub-id pub-id-type="pmid">12547707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Ranke</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Faria</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Zanetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hochhegger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Marchiori</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Imaging of tuberous sclerosis complex: a pictorial review.</article-title>
            <source>Radiol Bras</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-54</page-range>
            <pub-id pub-id-type="pmid">28298732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cheon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Lattouf</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Jamal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>E527</fpage>
            <page-range>E527-E536</page-range>
            <pub-id pub-id-type="pmid">33213697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jinzaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Akita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mikami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oya</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Renal Angiomyolipomas: Classic, Fat-Poor, and Epithelioid Types.</article-title>
            <source>Semin Ultrasound CT MR</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-46</page-range>
            <pub-id pub-id-type="pmid">28237279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martignoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pea</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rocca</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Bonetti</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Renal pathology in the tuberous sclerosis complex.</article-title>
            <source>Pathology</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>505</fpage>
            <page-range>505-12</page-range>
            <pub-id pub-id-type="pmid">14660101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brimo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Latour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2010</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-22</page-range>
            <pub-id pub-id-type="pmid">20410812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamboli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ligato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ayala</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Benign tumors and tumor-like lesions of the adult kidney. Part II: Benign mesenchymal and mixed neoplasms, and tumor-like lesions.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-66</page-range>
            <pub-id pub-id-type="pmid">10640201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eble</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>1123</fpage>
            <page-range>1123-30</page-range>
            <pub-id pub-id-type="pmid">9331283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Logginidou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis.</article-title>
            <source>Chest</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">10631194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christiano</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Malignant transformation of renal angiomyolipoma.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>161</volume>
            <issue>6</issue>
            <fpage>1900</fpage>
            <page-range>1900-1</page-range>
            <pub-id pub-id-type="pmid">10332463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martignoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bonetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pea</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hes</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Svec</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vankalakunti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rogatko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gown</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-76</page-range>
            <pub-id pub-id-type="pmid">21263237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Logue</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Acker</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Sienko</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Best cases from the AFIP: angiomyolipomas in tuberous sclerosis.</article-title>
            <source>Radiographics</source>
            <year>2003</year>
            <season>Jan-Feb</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>241</fpage>
            <page-range>241-6</page-range>
            <pub-id pub-id-type="pmid">12533658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>209</volume>
            <issue>4</issue>
            <fpage>826</fpage>
            <page-range>826-835</page-range>
            <pub-id pub-id-type="pmid">28726505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schieda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kielar</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Al Dandan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Ten uncommon and unusual variants of renal angiomyolipoma (AML): radiologic-pathologic correlation.</article-title>
            <source>Clin Radiol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>206</fpage>
            <page-range>206-20</page-range>
            <pub-id pub-id-type="pmid">25468637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>New radiologic classification of renal angiomyolipoma: frequently asked questions.</article-title>
            <source>Clin Imaging</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>55</volume>
            <fpage>156</fpage>
            <page-range>156-160</page-range>
            <pub-id pub-id-type="pmid">30825810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Shon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT.</article-title>
            <source>Radiology</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>230</volume>
            <issue>3</issue>
            <fpage>677</fpage>
            <page-range>677-84</page-range>
            <pub-id pub-id-type="pmid">14990834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>MDF</given-names>
              </name>
              <name>
                <surname>Katlariwala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Performance of MRI in the Detection of Renal Lipid-Poor Angiomyolipomas: A Systematic Review and Meta-Analysis.</article-title>
            <source>Radiology</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>296</volume>
            <issue>3</issue>
            <fpage>511</fpage>
            <page-range>511-520</page-range>
            <pub-id pub-id-type="pmid">32602827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forman</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Melson</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>McClennan</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Hyperechoic renal cell carcinomas: increase in detection at US.</article-title>
            <source>Radiology</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>188</volume>
            <issue>2</issue>
            <fpage>431</fpage>
            <page-range>431-4</page-range>
            <pub-id pub-id-type="pmid">8327692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ascenti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zimbaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mazziotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaeta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Settineri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scribano</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of power Doppler and contrast-enhanced sonography in the differentiation of hyperechoic renal masses.</article-title>
            <source>Abdom Imaging</source>
            <year>2001</year>
            <season>Nov-Dec</season>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>654</fpage>
            <page-range>654-60</page-range>
            <pub-id pub-id-type="pmid">11907734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habibollahi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Bialo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nazif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faizi</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyperechoic Renal Masses: Differentiation of Angiomyolipomas from Renal Cell Carcinomas using Tumor Size and Ultrasound Radiomics.</article-title>
            <source>Ultrasound Med Biol</source>
            <year>2022</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>887</fpage>
            <page-range>887-894</page-range>
            <pub-id pub-id-type="pmid">35219511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steiner</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>FF</given-names>
              </name>
            </person-group>
            <article-title>The natural history of renal angiomyolipoma.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>150</volume>
            <issue>6</issue>
            <fpage>1782</fpage>
            <page-range>1782-6</page-range>
            <pub-id pub-id-type="pmid">8230504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Are there useful CT features to differentiate renal cell carcinoma from lipid-poor renal angiomyolipoma?</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>201</volume>
            <issue>5</issue>
            <fpage>1017</fpage>
            <page-range>1017-28</page-range>
            <pub-id pub-id-type="pmid">24147472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma with coexistent hemorrhagic aneurysm formation and fatty thrombus in inferior vena cava: a rare presentation.</article-title>
            <source>Abdom Imaging</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>180</fpage>
            <page-range>180-3</page-range>
            <pub-id pub-id-type="pmid">22450723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YN</given-names>
              </name>
            </person-group>
            <article-title>The differential imaging features of fat-containing tumors in the peritoneal cavity and retroperitoneum: the radiologic-pathologic correlation.</article-title>
            <source>Korean J Radiol</source>
            <year>2010</year>
            <season>May-Jun</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-45</page-range>
            <pub-id pub-id-type="pmid">20461188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Marlais</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wlodkowski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haeberle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Argumedo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Breysem</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fladrowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jouret</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lattouf</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lilien</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maleux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rozenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siemer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Devuyst</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rouvi&#x000e8;re</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes &#x00026; Kidney Working Group.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>402</fpage>
            <page-range>402-420</page-range>
            <pub-id pub-id-type="pmid">38443710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>New radiologic classification of renal angiomyolipomas.</article-title>
            <source>Eur J Radiol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>85</volume>
            <issue>10</issue>
            <fpage>1835</fpage>
            <page-range>1835-1842</page-range>
            <pub-id pub-id-type="pmid">27666625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Israel</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Hindman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hecht</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Krinsky</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The use of opposed-phase chemical shift MRI in the diagnosis of renal angiomyolipomas.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>184</volume>
            <issue>6</issue>
            <fpage>1868</fpage>
            <page-range>1868-72</page-range>
            <pub-id pub-id-type="pmid">15908544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahni</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Biopsy of renal masses: when and why.</article-title>
            <source>Cancer Imaging</source>
            <year>2009</year>
            <month>Jul</month>
            <day>06</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-55</page-range>
            <pub-id pub-id-type="pmid">19602467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>YU</given-names>
              </name>
              <name>
                <surname>Mortele</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Tuncali</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cibas</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Renal masses in the adult patient: the role of percutaneous biopsy.</article-title>
            <source>Radiology</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>240</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-22</page-range>
            <pub-id pub-id-type="pmid">16709793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lobo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Bitner</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Mikula</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Noona</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Cathro</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Schenkman</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Krupski</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Does renal mass biopsy influence multidisciplinary treatment recommendations?</article-title>
            <source>Scand J Urol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-32</page-range>
            <pub-id pub-id-type="pmid">31868063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ouzaid</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Autorino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fatica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Herts</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>McLennan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Remer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Haber</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention.</article-title>
            <source>BJU Int</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>114</volume>
            <issue>3</issue>
            <fpage>412</fpage>
            <page-range>412-7</page-range>
            <pub-id pub-id-type="pmid">24325283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benedik</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Amato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beaure d'Aug&#x000e8;res</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Feucht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fladrowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Macaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Touraine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Youroukos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas.</article-title>
            <source>Front Neurol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>972</fpage>
            <pub-id pub-id-type="pmid">33041968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cockerell</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Guenin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heimdal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bj&#x000f8;rnvold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Selmer</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Rouvi&#x000e8;re</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Renal Angiomyolipomas and Spontaneous Bleeding Related to Angiomyolipomas in Tuberous Sclerosis Complex Patients in France and Norway-a Questionnaire Study.</article-title>
            <source>Urology</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>104</volume>
            <fpage>70</fpage>
            <page-range>70-76</page-range>
            <pub-id pub-id-type="pmid">28232177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamakado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yanagawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture.</article-title>
            <source>Radiology</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>225</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <page-range>78-82</page-range>
            <pub-id pub-id-type="pmid">12354988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rimon</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Duvdevani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garniek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bensaid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ramon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morag</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding.</article-title>
            <source>Clin Radiol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>520</fpage>
            <page-range>520-6</page-range>
            <pub-id pub-id-type="pmid">16713423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sheinin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Crispen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Lohse</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Leibovich</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation.</article-title>
            <source>Urology</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>927</fpage>
            <page-range>927-32</page-range>
            <pub-id pub-id-type="pmid">18374399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c7;etin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000fc;y&#x000fc;kkurt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Evr&#x000fc;ke</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Renal angiomyolipoma during pregnancy: Case report and literature review.</article-title>
            <source>Turk J Obstet Gynecol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-121</page-range>
            <pub-id pub-id-type="pmid">28913054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preece</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mees</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dundee</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of haemorrhaging renal angiomyolipoma in pregnancy.</article-title>
            <source>Int J Surg Case Rep</source>
            <year>2015</year>
            <volume>7C</volume>
            <fpage>89</fpage>
            <page-range>89-92</page-range>
            <pub-id pub-id-type="pmid">25598402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Management of renal tumors during pregnancy: case reports.</article-title>
            <source>BMC Nephrol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>09</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <pub-id pub-id-type="pmid">33836679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Transarterial Embolization of Angiomyolipoma: A Systematic Review.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>194</volume>
            <issue>3</issue>
            <fpage>635</fpage>
            <page-range>635-9</page-range>
            <pub-id pub-id-type="pmid">25916674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Pello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hora</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuusk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tahbaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dabestani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abu-Ghanem</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Albiges</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Hofmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuczyk</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Marconi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merseburger</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Staehler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volpe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ljungberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bex</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bensalah</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.</article-title>
            <source>Eur Urol Oncol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-72</page-range>
            <pub-id pub-id-type="pmid">31171501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaggers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Somani</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Veeratterapillay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based protocol-led management of renal angiomyolipoma: A review of literature.</article-title>
            <source>Turk J Urol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>Supp. 1</issue>
            <fpage>S9</fpage>
            <page-range>S9-S18</page-range>
            <pub-id pub-id-type="pmid">32966208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Radzikowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nonomura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brakemeier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Whittemore</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sahmoud</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lincy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Mar</month>
            <day>09</day>
            <volume>381</volume>
            <issue>9869</issue>
            <fpage>817</fpage>
            <page-range>817-24</page-range>
            <pub-id pub-id-type="pmid">23312829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>ZF</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.</article-title>
            <source>J Urol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>192</volume>
            <issue>5</issue>
            <fpage>1424</fpage>
            <page-range>1424-30</page-range>
            <pub-id pub-id-type="pmid">24813310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>FMA</given-names>
              </name>
              <name>
                <surname>Filho</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Balbo</surname>
                <given-names>BEP</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>PDMM</given-names>
              </name>
              <name>
                <surname>Franzin</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Onuchic</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Apr</month>
            <day>19</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>8493</fpage>
            <pub-id pub-id-type="pmid">33875750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geynisman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kadow</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Shuch</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Matin</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Rampersaud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Milestone</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Plimack</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Zibelman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kutikov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smaldone</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Viterbo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Malizzia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Uzzo</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>204</volume>
            <issue>3</issue>
            <fpage>531</fpage>
            <page-range>531-537</page-range>
            <pub-id pub-id-type="pmid">32250730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>671</fpage>
            <page-range>671-676</page-range>
            <pub-id pub-id-type="pmid">30756282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Radzikowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brakemeier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Voi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peyrard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>e0180939</fpage>
            <pub-id pub-id-type="pmid">28792952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Zu</surname>
                <given-names>XB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>744050</fpage>
            <pub-id pub-id-type="pmid">34901059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ridolfi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Christopher Kingswood</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1000</fpage>
            <page-range>1000-1008</page-range>
            <pub-id pub-id-type="pmid">30053159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trelinska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dachowska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baranska</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stawiski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kotulska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fendler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mlynarski</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study).</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">27860334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inaba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Egawa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.</article-title>
            <source>Int J Urol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>780</fpage>
            <page-range>780-785</page-range>
            <pub-id pub-id-type="pmid">28905429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasongko</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Kademane</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chai Soon Hou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jocelyn</surname>
                <given-names>TXY</given-names>
              </name>
              <name>
                <surname>Zabidi-Hussin</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Rapamycin and rapalogs for tuberous sclerosis complex.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2023</year>
            <month>Jul</month>
            <day>11</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD011272</fpage>
            <pub-id pub-id-type="pmid">37432030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>909</fpage>
            <page-range>909-928</page-range>
            <pub-id pub-id-type="pmid">29757017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelsalam</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ahrar</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Ablation of Small Renal Masses.</article-title>
            <source>Tech Vasc Interv Radiol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>100674</fpage>
            <pub-id pub-id-type="pmid">32591194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leflore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Laparoscopic cryotherapy for pediatric angiomyolipoma: the first report.</article-title>
            <source>J Endourol</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-4; discussion 324</page-range>
            <pub-id pub-id-type="pmid">17444779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Elmajian</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Shingleton</surname>
                <given-names>WB</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous renal cryoablation of angiomyolipomas in patients with solitary kidneys.</article-title>
            <source>Urology</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>1246</fpage>
            <page-range>1246-9</page-range>
            <pub-id pub-id-type="pmid">19815260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castle</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gorbatiy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ekwenna</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leveillee</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency ablation (RFA) therapy for renal angiomyolipoma (AML): an alternative to angio-embolization and nephron-sparing surgery.</article-title>
            <source>BJU Int</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>384</fpage>
            <page-range>384-7</page-range>
            <pub-id pub-id-type="pmid">22176671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prevoo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van den Bosch</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Horenblas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency ablation for treatment of sporadic angiomyolipoma.</article-title>
            <source>Urology</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>188</fpage>
            <page-range>188-91</page-range>
            <pub-id pub-id-type="pmid">18455777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamatiou</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Moschouris</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marmaridou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kiltenis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kladis-Kalentzis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Malagari</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Combination of Superselective Arterial Embolization and Radiofrequency Ablation for the Treatment of a Giant Renal Angiomyolipoma Complicated with Caval Thrombus.</article-title>
            <source>Case Rep Oncol Med</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>8087232</fpage>
            <pub-id pub-id-type="pmid">27293932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregory</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency ablation of large renal angiomyolipoma: median-term follow-up.</article-title>
            <source>Cardiovasc Intervent Radiol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>682</fpage>
            <page-range>682-9</page-range>
            <pub-id pub-id-type="pmid">23354958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A new management strategy for renal angiomyolipomas: superselective arterial embolization in combination with radiofrequency ablation.</article-title>
            <source>Ann Transl Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>23</issue>
            <fpage>766</fpage>
            <pub-id pub-id-type="pmid">32042782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nozadze</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Heerwagen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Juhl Jensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>L&#x000f6;nn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>R&#x000f8;der</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Selective arterial embolization of renal angiomyolipomas: A 10-year experience.</article-title>
            <source>BJUI Compass</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-92</page-range>
            <pub-id pub-id-type="pmid">35475158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urciuoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Orazi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Livadoti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Foresi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Panunzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anichini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cialini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wlderk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cirelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colangelo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mongardini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Custureri</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Treatment of renal angiomyolipoma: surgery versus angioembolization.</article-title>
            <source>G Chir</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>34</volume>
            <issue>11-12</issue>
            <fpage>326</fpage>
            <page-range>326-31</page-range>
            <pub-id pub-id-type="pmid">24342162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sayedin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nabi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abdelrahman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Alhadi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Active Surveillance for Renal Angiomyolipoma Less Than 4 Centimeters: A Systematic Review of Cohort Studies.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>e22678</fpage>
            <pub-id pub-id-type="pmid">35371642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mues</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Palacios</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Haramis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Casazza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Badani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKiernan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Landman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Contemporary experience in the management of angiomyolipoma.</article-title>
            <source>J Endourol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>1883</fpage>
            <page-range>1883-6</page-range>
            <pub-id pub-id-type="pmid">20919915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schieda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Pedrosa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shinagare</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chandarana</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Curci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Doshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Israel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Remer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Renal and adrenal masses containing fat at MRI: Proposed nomenclature by the society of abdominal radiology disease-focused panel on renal cell carcinoma.</article-title>
            <source>J Magn Reson Imaging</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>917</fpage>
            <page-range>917-926</page-range>
            <pub-id pub-id-type="pmid">30693607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e9;l&#x000e9;non</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Merran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paraf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Correas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chr&#x000e9;tien</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Unusual fat-containing tumors of the kidney: a diagnostic dilemma.</article-title>
            <source>Radiographics</source>
            <year>1997</year>
            <season>Jan-Feb</season>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-44</page-range>
            <pub-id pub-id-type="pmid">9017804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potretzke</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Potretzke</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bauman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mobley</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Figenshau</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Computed Tomography and Magnetic Resonance Findings of Fat-Poor Angiomyolipomas.</article-title>
            <source>J Endourol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-128</page-range>
            <pub-id pub-id-type="pmid">27897036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeon</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Rha</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients.</article-title>
            <source>Urology</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>574</fpage>
            <page-range>574-9</page-range>
            <pub-id pub-id-type="pmid">20303148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Chatelain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siddaiah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Dandan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Narayanasamy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schieda</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>CT imaging of solid renal masses: pitfalls and solutions.</article-title>
            <source>Clin Radiol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>72</volume>
            <issue>9</issue>
            <fpage>708</fpage>
            <page-range>708-721</page-range>
            <pub-id pub-id-type="pmid">28592361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Pandharipande</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Chandarana</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Solid renal masses: what the numbers tell us.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>202</volume>
            <issue>6</issue>
            <fpage>1196</fpage>
            <page-range>1196-206</page-range>
            <pub-id pub-id-type="pmid">24848816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahl</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Simeone</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Iliopoulos</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Saylor</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>22</day>
            <volume>379</volume>
            <issue>21</issue>
            <fpage>2064</fpage>
            <page-range>2064-2072</page-range>
            <pub-id pub-id-type="pmid">30462933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Computerized tomography characteristics that differentiate angiomyolipomas from liposarcomas in the perinephric space.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>167</volume>
            <issue>2 Pt 1</issue>
            <fpage>490</fpage>
            <page-range>490-3</page-range>
            <pub-id pub-id-type="pmid">11792904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Novick</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Exophytic noninvasive growth pattern of renal angiomyolipomas: implications for nephron sparing surgery.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>165</volume>
            <issue>2</issue>
            <fpage>513</fpage>
            <page-range>513-4</page-range>
            <pub-id pub-id-type="pmid">11176411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Saggar-Malik</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma.</article-title>
            <source>Clin Radiol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>665</fpage>
            <page-range>665-73; discussion 663-4</page-range>
            <pub-id pub-id-type="pmid">16038693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avila</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Active Surveillance of Nonfatty Renal Masses in Patients With Lymphangioleiomyomatosis: Use of CT Features and Patterns of Growth to Differentiate Angiomyolipoma From Renal Cancer.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>209</volume>
            <issue>3</issue>
            <fpage>611</fpage>
            <page-range>611-619</page-range>
            <pub-id pub-id-type="pmid">28678574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeoh</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>Navaratnam</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCafferty</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2014</year>
            <month>Oct</month>
            <day>03</day>
            <volume>9</volume>
            <fpage>151</fpage>
            <pub-id pub-id-type="pmid">25277108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>mTOR inhibitors in renal cell carcinoma.</article-title>
            <source>Therapy</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>359</fpage>
            <page-range>359-367</page-range>
            <pub-id pub-id-type="pmid">21894244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>An update on recent developments in rupture of renal angiomyolipoma.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>97</volume>
            <issue>16</issue>
            <fpage>e0497</fpage>
            <pub-id pub-id-type="pmid">29668633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Restrepo</surname>
                <given-names>JC&#x000c1;</given-names>
              </name>
              <name>
                <surname>Millan</surname>
                <given-names>DAC</given-names>
              </name>
              <name>
                <surname>Sabogal</surname>
                <given-names>CAR</given-names>
              </name>
              <name>
                <surname>Bernal</surname>
                <given-names>AFP</given-names>
              </name>
              <name>
                <surname>Donoso</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.</article-title>
            <source>J Kidney Cancer VHL</source>
            <year>2022</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-41</page-range>
            <pub-id pub-id-type="pmid">35096516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17578.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacKeigan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.</article-title>
            <source>Neuro Oncol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>1550</fpage>
            <page-range>1550-9</page-range>
            <pub-id pub-id-type="pmid">26289591</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
